Table 2.

Emerging trends in PKU management.

Disorder	Treatment	Biotech/Pharmaceutical Company	Stage of Development
PKU	Microbe therapy (SYNB1618)	Synlogic (https://www.synlogictx.com/)	Phase II clinical trail
	mRNA therapy (mRNA-3283)	Moderna (https://www.modernatx.com/)	Preclinical development
	Small molecule therapy	Agios Pharmaceuticals (https://www.agios.com/), Camp4 (https://www.camp4tx.com/)	Preclinical development
	Red blood cell therapy (RTX-134)	Rubius Therapeutics (https://www.rubiustx.com/)	Discontinued in Phase 1b trial